To study the role of CTGF in post-MI cardiac repair and LV remodeling, we antagonized the function of CTGF with a mAb. Vainio et al.
SUMMARY

Myocardial infarction (MI)
Patients with heart failure (HF) show elevated levels of plasma CTGF, which correlates with the severity of the disease (5) . Plasma levels of CTGF are also useful in differentiating acute HF patients from patients with other causes of dyspnea and peripheral edema (6) . CTGF expression in the myocardium is also induced in various animal models of myocardial fibrosis (for review, see Daniels et al. [7] and Leask [8] ). Cardiomyocyte-specific overexpression of CTGF in transgenic mice alone did not induce fibrosis but did enhance pressure overloadÀinduced cardiac fibrosis (9). On the other hand, pressure overload induced fibrosis was not attenuated in mice where CTGF was deleted in cardiomyocytes and cardiac fibroblasts (10), but not from other cell types in which CTGF may have been produced (11) . However, no data are available from studies in which the function of CTGF was antagonized in the ischemic heart or during post-MI fibrotic remodeling. (14) , and genetic cardiomyopathy (15, 16) . In the present study, we aimed to investigate the role of CTGF in cardiac repair following MI, in post-MI cardiac fibrosis, and in acute ischemiaÀreperfusion (I/R) injury. 
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Antagonizing the Function of CTGF in the Ischemic Heart F E B R U A R Y 2 0 1 9 : 8 3 -9 4 after initiating treatment, echocardiography analysis showed no difference in LV structure or function between the MI groups (Supplemental Table 1 ).
Analysis of harvested hearts after 6 weeks showed that CTGF mAb treatment resulted in a reduced heart weight to body weight ratio compared with the IgGtreated mice (p < 0.01) ( Figure 3A) . Echocardiography analysis at 6 weeks showed that mice treated with CTGF mAb had significantly lower LV mass and left atrial size (p < 0.01 and p < 0.05, respectively) ( Figure 3A) . No difference was observed in LV systolic function. Full echocardiography data are listed in Supplemental Table 2 . 
CTGF mAb HAS NO EFFECT ON INFARCT SIZE FOLLOWING MYOCARDIAL I/R INJURY (STUDY III).
To assess if antagonizing the function of CTGF affected acute cardiac I/R injury, wild-type mice were subjected to 30 min of ischemia followed by reperfusion (Study III) (Figure 1) . Analysis for cardiac injury by determination of apoptosis at 3 h after reperfusion showed no difference between the control IgG and CTGF mAb treatments ( Figure 4A ). When assessed 24 h after reperfusion, CTGF mAb treatment had no effect on the size of the area at risk ( Figure 4B) . Analysis of infarct size revealed no difference between the groups, which suggested that CTGF mAb had no effect on cardiomyocyte viability following I/R injury ( Figure 4B) . Echocardiography analysis at 24 h after reperfusion showed no difference in LV structure or function between the groups (Supplemental Table 4 ). Values are mean AE SD. The mice were subjected to myocardial infarction (MI), and 3 days after surgery randomly divided to receive either immunoglobulin (IgG) vehicle or connective tissue growth factor (CTGF) monoclonal antibody (mAb) for 4 days, and subjected to echocardiography analysis. LV mass and heart weight versus body weight (HW/BW) were analyzed. *p < 0.05. †p < 0.01. ‡p < 0.001 versus sham. §p < 0.05 versus MI þ IgG.
CO ¼ cardiac output; E/E 0 ¼ mitral E/E 0 ratio; EF ¼ ejection fraction; FS ¼ fractional shortening; HR ¼ heart rate; IVRT ¼ isovolumic relaxation time; LV ¼ left ventricular; LVEDD ¼ LV enddiastolic dimension; LVESD ¼ end-systolic dimension; LVEDPW ¼ LV end-diastolic posterior wall thickness; LVESPW ¼ LV end-systolic posterior wall thickness; LVED Vol ¼ LV end-diastolic volume; LVES Vol ¼ LV end-systolic volume, SV ¼ stroke volume.
FIGURE 3 CTGF mAb Protects Against Post-MI LV Hypertrophy and Fibrosis (Study II)
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The effect of CTGF inhibition on central signaling mechanisms in the ischemic heart was assessed 3 h after reperfusion with Western blotting. Analysis for reperfusion injury salvage kinase pathways in the ischemic area showed no difference in phosphorylation of protein kinase B (Akt) or ERK between the mice treated with IgG or CTGF mAb ( Figure 4C) . In contrast, phosphorylation of JNK2 and the signal transducer and activator of transcription 3 were significantly increased in hearts of mice treated with CTGF mAb ( Figure 4C ). CTGF mAb had no effect on SMAD, p38, or protein kinase C (PKC)-a phosphorylation ( Figure 4C ).
JNK PATHWAY MEDIATES EFFECTS OF CTGF mAb.
To more directly investigate the molecular function of CTGF mAb, we treated human cardiac FBs with CTGF mAb. Immunoblotting showed that treatment with CTGF mAb modestly reduced both basal and TGF-b1-induced aSMA and collagen-1 expression ( Figure 5A) . Examination of the affected signaling pathways showed that similar to findings in vivo, CTGF mAb induced JNK2 phosphorylation ( Figure 5A ). Antagonizing the function of CTGF also modestly reduced focal adhesion kinase (FAK) phosphorylation, but had no effect on ERK or SMAD2 phosphorylation ( Figure 5A ).
Quantitative analysis for the effect of CTGF mAb on collagen production showed that CTGF mAb significantly reduced both basal and TGF-b1-induced collagen production, but had no effect on basal or TGF-b1-induced FB proliferation ( Figure 5B ). We then In addition, novel approaches, such as inhibition of fibronectin polymerization, may provide novel therapeutic approaches (21) . In the present study, we investigated the potential of CTGF mAb therapy in protecting the heart from MI-induced injury and fibrosis.
TREATMENT WITH CTGF mAb DURING CARDIAC REPAIR. Repair of the infarcted heart can be divided into 3 overlapping phases: the inflammatory, proliferative, and maturation phases (22) . The inflammatory phase in mouse hearts subjected to I/R injury lasts up to 72 hours after injury and is likely longer in hearts undergoing permanent MI. This is followed by a proliferative phase (days 3 to 7), which is charac- Mice were subjected to MI and 1 week after surgery randomly divided to receive IgG vehicle or CTGF mAb for 6 weeks. week after MI and also improved survival. We also found that CTGF mAb treatment started at day 3 after MI reduced infarct scar thinning and infarct expansion. Infarct expansion is associated with a decrease in LV systolic function and increased infarct rupture, which most often occurs at the infarct border zone during the first week after MI (24, 25) . Vainio et al.
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